Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating

CoffeeNFTs · 2026-03-26T20:12:28+00:00

Arcutis Biotherapeutics recently achieved a Relative Strength Rating of 82, indicating strong market performance. The stock surpassed a buy point but is now considered extended. Despite 0% earnings growth last quarter, sales surged by 81%, ranking it 61st in its industry.

CoffeeNFTs

2026-03-26 20:12:28

Abstract generation in progress

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Arcutis Biotherapeutics (ARQT) just hit that mark, with a jump from 79 to 82 Thursday.

				    ↑
					X

This video file cannot be played.(Error Code: 102630)

								Market Breadth: How This Indicator Reveals Hidden Weakness In A Bull Market
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						Market Breadth: How This Indicator Reveals Hidden Weakness In A Bull Market

Looking For The Best Stocks To Buy And Watch? Start Here

IBD’s unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock’s price action over the trailing 52 weeks matches up against that of all other stocks.

Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating of above 80 in the early stages of their moves.

Arcutis Biotherapeutics is now considered extended and out of buy range after clearing a 17.75 buy point in a second-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

Arcutis Biotherapeutics posted 0% earnings growth last quarter, while sales growth came in at 81%.

Arcutis Biotherapeutics earns the No. 61 rank among its peers in the Medical-Biomed/Biotech industry group. Eton Pharmaceuticals (ETON), Kiniksa Pharmaceuticals (KNSA) and Amicus Therapeutics (FOLD) are among the top 5 highly rated stocks within the group.

This article was created automatically with Stats Perform’s Wordsmith software using data and article templates supplied by Investor’s Business Daily. An IBD journalist may have edited the article.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.